Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.
Open accessThe DOI matches its Crossref record; 191 of the 191 references it cites were found in a registry or an index.
Abstract
Pathological angiogenesis-driven by an imbalance of pro- and antiangiogenic signaling-is a hallmark of many diseases, both malignant and benign. Unlike in the healthy adult in which angiogenesis is tightly regulated, such diseases are characterized by uncontrolled new vessel formation, resulting in a microvascular network characterized by vessel immaturity, with profound structural and functional abnormalities. The consequence of these abnormalities is further modification of the microenvironment, often serving to fuel disease progression and attenuate response to conventional therapies. In this article, we present the "vascular normalization" hypothesis, which states that antiangiogenic therapy, by restoring the balance between pro- and antiangiogenic signaling, can induce a more structurally and functionally normal vasculature in a variety of diseases. We present the preclinical and clinical evidence supporting this concept and discuss how it has contributed to successful treatment of both solid tumors and several benign conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Antiangiogenic agents are thought to normalize tumor vasculature to allow for better delivery of chemotherapy.”
From Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma (2024) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 1×
“Intriguingly, however, the addition of anti-VEGF therapy to systemic chemotherapy has often proven to be an effective strategy, with patient outcomes superior to chemotherapy alone (Hurwitz et al. 2004; Sandler et al. 2006; Miller et al. 2007; Saltz et al. 2008; Reck et al. 2009).”
BackgroundTumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187 · cited 2×
“…(VEGF) as the principal driver of tumor angiogenesis (Senger et al. 1983; Leung et al. 1989) rapidly prompted the development of antiangiogenic drugs to treat cancer, designed to inhibit VEGF’s activity and hence promote vascular regression and tumor starvation (Folkman 1971; Kim et al. 1993).”
BackgroundRanibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761 · cited 1×
“Intriguingly, however, the addition of anti-VEGF therapy to systemic chemotherapy has often proven to be an effective strategy, with patient outcomes superior to chemotherapy alone (Hurwitz et al. 2004; Sandler et al. 2006; Miller et al. 2007; Saltz et al. 2008; Reck et al. 2009).”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Self-citationMolecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
Self-citationVascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986 · cited 2×
“The discovery of vascular endothelial growth factor (VEGF) as the principal driver of tumor angiogenesis (Senger et al. 1983; Leung et al. 1989) rapidly prompted the development of antiangiogenic drugs to treat cancer, designed to inhibit VEGF’s activity and hence promote vascular regression and tumor starvation (Folk…”
BackgroundTumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391 · cited 1×
“Unlike physiological angiogenesis, blood vessel development in solid tumors is not tightly controlled, but rather occurs relentlessly (Dvorak 1986; Chung et al. 2010; Carmeliet and Jain 2011).”
BackgroundCancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Cited by
Items 301–371 of 371
Chen, T. W., Lin, C., Yeh, D., Tseng, L., Rau, K.-M., Chen, B., Chao, T., Huang, S., Chang, D., Chen, I., et al. (2023) · Journal of Cancer Research and Practice · doi:10.4103/ejcrp.ejcrp-d-23-00001 · Cited by 1
Majewska, A., Brodaczewska, K. K., Filipiak-Duliban, A., & Kiéda, C. (2023) · Biochemistry and Cell Biology · doi:10.1139/bcb-2023-0047 · Cited by 1
Anai, M., Saruwatari, K., Imamura, K., Fujino, K., Jodai, T., Sakata, S., Iyama, S., Tomita, Y., Saeki, S., Ichiyasu, H., et al. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-23-1723 · Cited by 2
“VEGF plays an important role in tumor angiogenesis and leads to leakage from microvessels in tumor tissues and elevation of interstitial fluid pressure, which decreases drug delivery and results in drug resistance (22-25).”
The role of the integrin β3 adhesome in angiogenesis
Atkinson, S. J. (2018) · UEA Digital Repository (University of East Anglia) · Cited by 1
Celebrating the 1945 JNCI pioneering contribution to antiangiogenic therapy for cancer
Tosato, G., & Wang, Y. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae181 · Cited by 1
Intravital Microscopy for Molecular Imaging in Cancer Research
Yu, H., & Gambhir, S. S. (2014) · Springer eBooks · doi:10.1007/978-94-017-9361-2_12
The control of tumor vessels: what you would not expect from a neural adhesion molecule
Angiolini, F., & Cavallaro, U. (2015) · Molecular & Cellular Oncology · doi:10.4161/23723556.2014.982045
“This theory has received support from a number of preclinical and clinical studies.(9) Our findings point to L1 neutralization as a novel strategy to induce vessel normalization, providing the rationale for testing whether this increases the efficacy of anticancer treatments (Fig.”
ResultNizard, M. (2015) · theses.fr (ABES) · doi:10.70675/3d3079abz13a3z421bzb96ezd30e886c45b1 · Cited by 1
Pharmacogenomics for Oral Disease
Kornman, K. S., Duff, G. W., Huttner, K. M., Polverini, P. J., & Hu, J. C. ‐. (2015) · Springer eBooks · doi:10.1007/978-3-319-17942-1_17
“lating vascular normalization and decreasing intratumoral pressure [41, 52, 92].”
BackgroundModulation of Oxidative Stress Influences Tumor Response to Therapy.
Boss, M. (2016) · NCSU Libraries Repository (North Carolina State University Libraries)
Neoplastic Non-Angiogenic Growth by Means of Vascular Co-Option
Pezzella, F. (2015) · Journal of Clinical & Experimental Pathology · doi:10.4172/2161-0681.1000232
Anti-angiogenic Targeting in Metastatic Colorectal Cancer Therapy
Zander, T., Goede, V., & Hallek, M. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-31215-6_16-1
Korth, M. (2017) · OPen Access Repositorium der Universität Ulm (OPARU) (Ulm University) · doi:10.18725/oparu-4364
Un lien entre normalisation de l’angiogenèse et stimulation de l’immunité antitumorale
Soares, D. G., & Lotz, J. (2017) · ONCOLOGIE · doi:10.1007/s10269-017-2732-y
“Il a été suggéré que ce paradoxe pouvait s’expliquer par la dose utilisée et la normalisation des vaisseaux sanguins qui peut être parfois observée [3].”
Tejchman, A. (2017) · theses.fr (ABES) · doi:10.70675/c66cab0bz93c1z4199za2fdz0cbfb889d2c3 · Cited by 1
“This random distribution of vessels does not permit an efficient blood flow in some regions and while it is excessive inothers[63][64].”
BackgroundInhibition of HSPs for Enhanced Immunity
Fecek, R. J., Raveendran, S., Chelvanambi, M., & Storkus, W. J. (2018) · Springer eBooks · doi:10.1007/978-3-319-69042-1_9
Benefits and Pitfalls of Tumor Vessel Normalization
Park, J., Park, I., & Koh, G. Y. (2018) · Springer eBooks · doi:10.1007/978-3-319-31215-6_46-1
Catan, A. (2018) · theses.fr (ABES) · doi:10.70675/43411df7z16b7z4570za580zf1ace0e7526b · Cited by 2
11β-hydroxysteroid dehydrogenase type I inhibition in solid tumours
Davidson, C. (2018) · ERA
INTRAPLAQUE ANGIOGENESIS AND THERAPEUTIC TARGETING OF ANGIOGENESIS
Parma, L. (2020) · Leiden Repository (Leiden University) · doi:10.13130/parma-laura_phd2020-10-15
Ribatti, D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822803-6.00007-7
Anti-angiogenic Targeting in Metastatic Colorectal Cancer Therapy
Zander, T., Goede, V., & Hallek, M. J. (2019) · Springer eBooks · doi:10.1007/978-3-319-33673-2_16
Anai, M., Saruwatari, K., Imamura, K., Fujino, K., Jodai, T., Sakata, S., Iyama, S., Tomita, Y., Saeki, S., Ichiyasu, H., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2462834/v1
Anai, M., Saruwatari, K., Imamura, K., Fujino, K., Jodai, T., Sakata, S., Iyama, S., Tomita, Y., Saeki, S., Ichiyasu, H., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2499742/v1
Sheldon, H., Bridges, E., Silva, I., Masiero, M., Favara, D. M., Wang, D., Leek, R., Snell, C. E., Roxanis, I., Kreuzer, M., et al. (2023) · doi:10.1158/1541-7786.c.6545234
Peña, C. M., Lee, A. H., Frare, M. F., Ghosh, D., & Dawson, M. (2023) · Current cancer research · doi:10.1007/978-3-031-22802-5_4 · Cited by 1
The efficacy and safety of thalidomide for treating metastatic breast cancer: a systematic review
Wang, X., Xie, Y., Jing, G., Yu, F. F., & Ren, Y. (2020) · Oncology and Translational Medicine · doi:10.1007/s10330-019-0341-1
“Abnormal tumor vessels demonstrate reduced perivascular cell (PVC) coverage, endothelial cell (EC) dissociation, and excess tumor vessel permeability, presenting opportunities for cells to metastasize [7].”
Background王, 承. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.13122626
Cuménal, M. (2021) · theses.fr (ABES) · doi:10.70675/a07c8315ze312z49e9z8612z9de041b5419d
Hou, J., Zhang, H., Liu, J., Zhao, Z., Wang, J., Lu, Z., Hu, B., Zhou, J., Zhao, Z., Feng, M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.11981574
Hou, J., Zhang, H., Liu, J., Zhao, Z., Wang, J., Lu, Z., Hu, B., Zhou, J., Zhao, Z., Feng, M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.11981577
Koirala, A., Marshak‐Rothstein, A., Ksander, B. R., & Gregory-Ksander, M. S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1898554
Heriz, M. H., Mahmood, A. A. R., Tahtamouni, L. H., Al-Sakhen, M. F., Kanaan, S. I., Saleh, K. M. M., & Yasin, S. R. (2024) · Current Cancer Drug Targets · doi:10.2174/0115680096307334240429050730
Zeng, J., Ai, Y., Lu, X., Wang, H., Hu, Q., Guo, C., Zeng, Y., Ma, X., Tang, J., & Efferth, T. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.5016626
Pangua, C., Espuelas, S., Simón, J. A., Collantes, M., Peñuelas, I., Calvo, A., & Irache, J. M. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01941-6
Desai, M. K., Parmar, N. B., Raghani, N. R., Patel, R. B., Shah, D. D., Chorawala, M. R., & Prajapati, B. G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33536-5.00018-3
Hubbard, J. M., Zemla, T., Zhu, M., Graham, R. P., Jin, Z., Mitchell, J. L., Novo, E., Végh, É., Lőrincz, O., Csiszovszki, Z., et al. (2025) · JCO oncology advances. · doi:10.1200/oa-25-00108
Computational Systems Biology for the VEGF Family in Angiogenesis
Lee, Y., Keku, I., Fang, Y., Weddell, J. C., & Imoukhuede, P. I. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-15734-9.00079-0
Hou, J., Zhang, H., Liu, J., Zhenjun, Z., Wang, J., Lu, Z., Hu, B., Zhou, J., Zhao, Z., Feng, M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.11981571
Additional file 1 of Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma
Garcia‐Romero, N., Palacín-Aliana, I., Madurga, R., Carrión-Navarro, J., Esteban-Rubio, S., Jiménez, B., Collazo, A., Pérez‐Rodríguez, F. J., Ortiz de Mendivil, A., Fernández-Carballal, C., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12530594
Hou, J., Zhang, H., Liu, J., Zhenjun, Z., Wang, J., Lu, Z., Hu, B., Zhou, J., Zhao, Z., Feng, M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.11981568
Hou, J., Zhang, H., Liu, J., Zhenjun, Z., Wang, J., Lu, Z., Hu, B., Zhou, J., Zhao, Z., Feng, M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.11981580
Afonso, M. E. V. (2016) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Low doses of ionizing radiation induce angiogenesis after radiotherapy
Ferreira, J. F. P. (2016) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Mohammad, S. (2022) · Nottingham ePrints (University of Nottingham)
Esteves, M. J. R. D. S. (2022) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/6f7y-mv74
Costabile, F., Pierini, S., Perales-Linares, R. F., Leli, N. M., Bear, A. S., Koch, C. J., Carreno, B. M., Lotze, M. T., Singh, L. N., Falck, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.30.702567
“Given the requirement of functional vasculature for T cells infiltration and the increased intratumorally CD8 ⁺ T-cell infiltration we observed with TAMAs + ICI, we next investigated whether combination treatment modulated the tumor vasculature 24,25 .”
Étude des propriétés oncogéniques des membres de la famille SNAIL
Gras, B. (2012) · theses.fr (ABES) · doi:10.70675/6bc4d1e2zd152z4fa2z9ee7zb005983eb581
Scandolera, A. (2015) · theses.fr (ABES) · doi:10.70675/9489926azab7cz44c6zb691zf91e3164f609 · Cited by 1
Identification of therapeutic targets of nucleolin-related pathways in pancreatic cancer therapy
Raineri, F. (2020) · theses.fr (ABES) · doi:10.70675/b0a30a01z777cz4da7z90cbz3e9a95dd1630
Tarrass, M. A. (2023) · theses.fr (ABES) · doi:10.70675/aea61e27z0cadz4558za7acz92d960d99b81 · Cited by 1
Tang, N., Guan, P., Yang, D., Zhang, L., Lin, L., Li, T., Wu, A., & Lu, Q. (2026) · BMC Gastroenterology · doi:10.1186/s12876-026-04902-6
“This leads to a measurable decrease in CEUS perfusion parameters (IMAX and AUC) before tumor shrinkage becomes detectable [21, 22].”
Venu, A., Kumar, A., Ezhil, I., Sahu, M. R., Bai, X., Pohar, K. S., & Basu, S. (2026) · The FASEB Journal · doi:10.1096/fj.202600843r · Cited by 1
Sun, X. (2026) · cIRcle (University of British Columbia) · doi:10.14288/1.0452810
Chemical Ingredients and Antitumor Application of Dragon’s Blood
Zhang, S. J., Zhu, S., Liu, X., Zhou, D., Tang, X., Zhang, D., Wang, J., Wei, Y., & Li, H. (2026) · Natural Product Communications · doi:10.1177/1934578x261471414
Kordparijaei, E., Ferdosi-Shahandashti, E., & Harasani, Z. (2026) · Tissue Engineering Part B Reviews · doi:10.1177/19373368261469473
Tisza, A., Török, S., Sugihara, Y., Horváth, Z., Gellert, Á., Bugyik, E., Berta, J., Kovács, I., Bárány, N., Marko‐Varga, G., et al. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179293
Nanocarrier-based drug delivery systems for remodeling the melanoma tumor microenvironment
Wang, H., Sun, C., Wang, H., Shen, W., Ren, G., & Wang, M. (2026) · Journal of drug targeting · doi:10.1080/1061186x.2026.2743182
Milian, L. M., Geindreau, M., Pignol, C., & Végran, F. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00612-3
“In murine models, the so-called “normalization window” occurs between 2 and 8 days following anti-VEGFR2 administration [176, 177].”
Metadata
- Authors
- Goel, S., Wong, A. H.-K., & Jain, R. K.
- Affiliations
- Harvard University (US)
- ORCID
- Goel, S.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2011-10-18
- Volume
- 2
- Issue
- 3
- Pages
- a006486-a006486
- ISSN
- 2157-1422 (ISSN-L)
- PMC
- PMC3282493
- OpenAlex
- W2115852392
- Cited by
- 352
- References
- 191
- Citations by year
- 2026: 14 · 2025: 23 · 2024: 22 · 2023: 27 · 2022: 18 · 2021: 31 · 2020: 30 · 2019: 23 · 2018: 30 · 2017: 38 · 2016: 29 · 2015: 28 · 2014: 21 · 2013: 13 · 2012: 5
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense (W81XWH1010016, W81XWH)
- US-UK Fulbright Commission
- Fulbright Australia
- National Institutes of Health (W81XWH, CA126642, CA115767, R01-CA85140)
- National Cancer Institute (R01CA115767, W81XWH-10-1-0016, R01 CA 85140, R01CA085140, P01CA080124, R01CA126642, P01-CA-80124)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- vascular normalization, pathological angiogenesis, anti-angiogenic therapy, tumor vasculature, tumor microenvironment, solid tumors
- MeSH terms
- Cytotoxins, Humans, Macular Degeneration, Neoplasms, Neuroma, Acoustic, Psoriasis, Telangiectasia, Hereditary Hemorrhagic, Disease Progression, Neovascularization, Physiologic, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Angiopoietin-2, Microvessels, Plaque, Atherosclerotic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.